The TNM staging system and breast cancer

Lancet Oncology

Volumn 4, Issue 1, 2003, Pages 56-60

  Benson, John R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER CLASSIFICATION; CANCER SIZE; CANCER STAGING; CLINICAL EXAMINATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; NOTE; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0037245084     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)00961-6     Document Type: Note

References (23)

1. Denoix PF. Bull Inst Nat Hyg (Paris) 1944; 1: 1-69 and 5-82.
2. International Union Against Cancer (UICC). TMN Classification of malignant tumours. Geneva: UICC, 1968.
3. Thornton H. The voice of the breast cancer patient - a lonely cry in the wilderness. Eur J Cancer 1997; 33: 825-28.
4. Querci della Rovere G and Benson JR. Ipsilateral local recurrence of breast cancer: determinant or indicator of poor prognosis? Lancet Oncol 2002; 3: 183-87.
5. Barr LC and Baum M. Time to abandon TMN staging of breast cancer. Lancet 1992; 339: 915-17.
6. Yang WT, Lam WW, Cheung H, et al. Sonographic magnetic resonance imaging and mammographic assessments of preoperative size of breast cancer. J Ultrasound Med 1997; 16: 791-06.
7. Rizzatto G and Chersevani R. Breast ultrasound and new techniques. Eur J Radiol 1998; 27 (suppl 2): 5242-09.
8. Kramer S, Shultz-Wendtland R, Hagedorn K et al. Magnetic resonance imaging and its role in the diagnosis of multicentric breast cancer. Anticancer Res 1998; 18: 2163-04.
9. Benson JR. Time out for TMN. Lancet 1992; 339: 1234.
10. Dent DM. Axillary lymphadenectomy for breast cancer. Arch Surg 1996; 131: 1125-27.
11. Schottenfeld D, Nash AG, Robbins GF, et al. Ten year results of the treatment of primary operable breast carcinoma: a summary of 304 patients evaluated by the TNM system. Cancer 1976; 38: 1001-07.
12. Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-42.
13. Singletary E, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer Staging system for breast cancer. J Clin Oncol 2002; 20: 3628-36.
14. Carter CL, Allen C, Hensen DE. Relation of tumour size, lymph node status and survival in 24 740 breast cancer cases. Cancer 1989; 63: 181-07.
15. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node positive pre-menopausal women with breast cancer. NEJM 1997; 337: 956-62.
16. Overgaard M, Hansen PS, Overgaard J, et al. Post-operative radiotherapy in high-risk pre-menopausal women with breast cancer who receive adjuvant chemotherapy. NEJM 1997; 337: 949-55.
17. Cote RJ, Peterson HF, Chaiwun B et al. Role of immunohistochemical detection of lymph node metastases in management of breast cancer. Lancet 1999; 354: 896-901.
18. Querci della Rovere G and Benson JR. Classification of isolated tumour cells and micrometastasis. Cancer 2001; 89: 707-09.
19. Bedrosian I, Reynolds C, Faries MB, et al. Predicting the risk of metastasis to non-sentinel nodes in breast cancer patients with metastasis to the sentinel node. Breast Cancer Res Treat 1999; 57: 35.
20. Singletary SE. Systemic treatment following sentinel lymph node biopsy in breast cancer: who, what, and why? Am Coll Surg 2001; 192: 220-30.
21. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index for primary breast cancer. Br J Cancer 1982; 45: 361-66.
22. Kollias J, Jurphy CA, Elston CW, et al. The prognosis of small primary breast cancers. Eur J Cancer 1999; 35: 908-12.
23. Yarbro JW, Page DL, Fielding LP, et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference. Cancer 1999; 86: 2436-46.